FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:905-916 August 30, 2007 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Osteoporosis, a major worldwide health problem, affects 4 million to 6 million women and 1 million to 2 million men in the United States. Even more people have decreased bone mass, which, in addition to other risk factors, can be a major therapeutic challenge.¹ Fractures, the most important consequence of osteoporosis, are associated with enormous costs and substantial morbidity and mortality. The prevention and treatment of this disease are therefore of paramount importance. Since postmenopausal osteoporosis is characterized by bone resorption that exceeds bone formation, antiresorptive agents can help to restore skeletal balance by reducing bone turnover, primarily at the . . . [Full Text of this Article]

Bone Remodeling and Modeling

Signals That Regulate Bone Formation

Bone Morphogenetic Proteins, Wnt, and Insulin-Like Growth Factor I

Parathyroid Hormone

Clinical Relevance of Anabolic Signaling Molecules

Parathyroid Hormone

Strontium Ranelate

Growth Hormone and IGF-I

Sclerostin Antagonism

Other Candidate Molecules for Anabolic Therapy

Antagonists of Dkk-1

Soluble Activin Receptors

The Osteoblast Proteasome and Its Inhibitors

Conclusions

Source Information

From the Department of Research, Saint Francis Hospital and Medical Center, Hartford, CT (E.C.); the University of Connecticut School of Medicine, Farmington (E.C.); the Department of Internal Medicine, University of Brescia, Brescia, Italy (A.G.); and the Department of Medicine, College of Physicians and Surgeons, Columbia University, New York (J.P.B.).

Address reprint requests to Dr. Canalis at the Department of Research, Saint Francis Hospital and Medical Center, 114 Woodland St., Hartford, CT 06105-1299, or at ecanalis@stfranciscare.org.

This article has been cited by other articles:

• Pearsall, R. S., Canalis, E., Cornwall-Brady, M., Underwood, K. W., Haigis, B., Ucran, J., Kumar, R., Pobre, E., Grinberg, A., Werner, E. D., Glatt, V., Stadmeyer, L., Smith, D., Seehra, J., Bouxsein, M. L. (2008). A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc. Natl. Acad. Sci. USA 105: 7082-7087 [Abstract] [Full Text]  
• Clay, P. G, Voss, L. E, Williams, C., Daume, E. C (2008). Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons. The Annals of Pharmacotherapy 42: 670-679 [Abstract] [Full Text]  
• Canalis, E. (2008). Notch Signaling in Osteoblasts. Sci Signal 1: pe17-pe17 [Abstract] [Full Text]  
• Anastasilakis, A. D, Goulis, D. G, Polyzos, S. A, Gerou, S., Pavlidou, V., Koukoulis, G., Avramidis, A. (2008). Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-{kappa}B ligand levels in women with established osteoporosis treated with teriparatide. Eur J Endocrinol 158: 411-415 [Abstract] [Full Text]  
• Farooki, A., Fornier, M., Girotra, M. (2007). Anabolic Therapies for Osteoporosis. NEJM 357: 2410-2411 [Full Text]  
• Ferrari, S., Seeman, E., Strewler, G. J. (2007). Clinical and Basic Research Papers August 2007 Selections. IBMS BoneKEy 4: 231-235 [Full Text]